Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

International consensus on quality standards for brain health-focused care in multiple sclerosis.

Hobart J, Bowen A, Pepper G, Crofts H, Eberhard L, Berger T, Boyko A, Boz C, Butzkueven H, Celius EG, Drulovic J, Flores J, Horáková D, Lebrun-Frénay C, Marrie RA, Overell J, Piehl F, Rasmussen PV, Sá MJ, Sîrbu CA, Skromne E, Torkildsen Ø, van Pesch V, Vollmer T, Zakaria M, Ziemssen T, Giovannoni G.

Mult Scler. 2018 Nov 1:1352458518809326. doi: 10.1177/1352458518809326. [Epub ahead of print]

PMID:
30381987
2.

Bevacizumab: Is the lower the better for glioblastoma patients in progression?

Sirven-Villaros L, Bourg V, Suissa L, Mondot L, Almairac F, Fontaine D, Paquis P, Burel-VandenBos F, Frenay M, Thomas P, Lebrun-Frenay C.

Bull Cancer. 2018 Oct 6. pii: S0007-4551(18)30231-5. doi: 10.1016/j.bulcan.2018.07.010. [Epub ahead of print]

PMID:
30301554
3.

Imaging spectrum of Bing-Neel syndrome: how can a radiologist recognise this rare neurological complication of Waldenström's macroglobulinemia?

Fitsiori A, Fornecker LM, Simon L, Karentzos A, Galanaud D, Outteryck O, Vermersch P, Pruvo JP, Gerardin E, Lebrun-Frenay C, Lafitte F, Cottier JP, Clerc C, de Seze J, Dietemann JL, Kremer S.

Eur Radiol. 2018 Jun 19. doi: 10.1007/s00330-018-5543-7. [Epub ahead of print]

PMID:
29922935
4.

MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study.

Tourbah A, Gout O, Vighetto A, Deburghgraeve V, Pelletier J, Papeix C, Lebrun-Frenay C, Labauge P, Brassat D, Toosy A, Laplaud DA, Outteryck O, Moreau T, Debouverie M, Clavelou P, Heinzlef O, De Sèze J, Defer G, Sedel F, Arndt C.

CNS Drugs. 2018 Jul;32(7):661-672. doi: 10.1007/s40263-018-0528-2.

5.

Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study.

Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, Bourre B, Ciron J, Collongues N, Brassat D, Cotton F, Papeix C, Durand-Dubief F, Laplaud D, Deschamps R, Cohen M, Biotti D, Ayrignac X, Tilikete C, Thouvenot E, Brochet B, Dulau C, Moreau T, Tourbah A, Lebranchu P, Michel L, Lebrun-Frenay C, Montcuquet A, Mathey G, Debouverie M, Pelletier J, Labauge P, Derache N, Coustans M, Rollot F, De Seze J, Vukusic S, Marignier R; OFSEP and NOMADMUS Study Group.

Neurology. 2018 May 22;90(21):e1858-e1869. doi: 10.1212/WNL.0000000000005560. Epub 2018 Apr 25.

PMID:
29695592
6.

Cervical spinal cord atrophy: An early marker of progressive MS onset.

Zeydan B, Gu X, Atkinson EJ, Keegan BM, Weinshenker BG, Tillema JM, Pelletier D, Azevedo CJ, Lebrun-Frenay C, Siva A, Okuda DT, Kantarci K, Kantarci OH.

Neurol Neuroimmunol Neuroinflamm. 2018 Jan 22;5(2):e435. doi: 10.1212/NXI.0000000000000435. eCollection 2018 Mar.

7.

Decreased prevalence of cancer in patients with multiple sclerosis: A case-control study.

Moisset X, Perié M, Pereira B, Dumont E, Lebrun-Frenay C, Lesage FX, Dutheil F, Taithe F, Clavelou P.

PLoS One. 2017 Nov 27;12(11):e0188120. doi: 10.1371/journal.pone.0188120. eCollection 2017.

8.

Multiple sclerosis treatments and the anti-JCV antibody index.

de Seze J, Lebrun-Frenay C.

Rev Neurol (Paris). 2017 Dec;173(10):e1. doi: 10.1016/j.neurol.2017.09.008. Epub 2017 Nov 2. No abstract available.

PMID:
29103667
9.

Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy.

Fissolo N, Pignolet B, Matute-Blanch C, Triviño JC, Miró B, Mota M, Perez-Hoyos S, Sanchez A, Vermersch P, Ruet A, de Sèze J, Labauge P, Vukusic S, Papeix C, Almoyna L, Tourbah A, Clavelou P, Moreau T, Pelletier J, Lebrun-Frenay C, Montalban X, Brassat D, Comabella M; Biomarkers and Response to Natalizumab for Multiple Sclerosis Treatment (BIONAT), Best EScalation Treatment in Multiple Sclerosis (BEST-MS), and the Société Francophone de la Sclérose En Plaques (SFSEP) Network.

Ann Neurol. 2017 Aug;82(2):186-195. doi: 10.1002/ana.24987. Epub 2017 Jul 22.

PMID:
28681388
10.

New insights into the burden and costs of multiple sclerosis in Europe: Results for France.

Lebrun-Frenay C, Kobelt G, Berg J, Capsa D, Gannedahl M; European Multiple Sclerosis Platform.

Mult Scler. 2017 Aug;23(2_suppl):65-77. doi: 10.1177/1352458517708125.

PMID:
28643588
11.

Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas.

Lasolle H, Cortet C, Castinetti F, Cloix L, Caron P, Delemer B, Desailloud R, Jublanc C, Lebrun-Frenay C, Sadoul JL, Taillandier L, Batisse-Lignier M, Bonnet F, Bourcigaux N, Bresson D, Chabre O, Chanson P, Garcia C, Haissaguerre M, Reznik Y, Borot S, Villa C, Vasiljevic A, Gaillard S, Jouanneau E, Assié G, Raverot G.

Eur J Endocrinol. 2017 Jun;176(6):769-777. doi: 10.1530/EJE-16-0979.

PMID:
28432119
12.

Multiple immune disorders after natalizumab discontinuation: After the CIRIS, the SIRIS?

Van Obberghen EK, Cohen M, Rocher F, Lebrun-Frenay C.

Rev Neurol (Paris). 2017 Apr;173(4):222-224. doi: 10.1016/j.neurol.2017.03.008. Epub 2017 Mar 31.

PMID:
28372806
13.

Erratum to 'HMGB1/anti-HMGB1 antibodies define a molecular signature of early stages of HIV-Associated Neurocognitive Disorders (HAND)'.

Gougeon ML, Poirier-Beaudouin B, Durant J, Lebrun-Frenay C, Saïdi H, Seffer V, Ticchioni M, Chanalet S, Carsenti H, Harvey-Langton A, Laffon M, Cottalorda J, Pradier C, Dellamonica P, Vassallo M.

Heliyon. 2017 Mar 16;3(3):e00259. doi: 10.1016/j.heliyon.2017.e00259. eCollection 2017 Mar.

14.

HMGB1/anti-HMGB1 antibodies define a molecular signature of early stages of HIV-Associated Neurocognitive Isorders (HAND).

Gougeon ML, Poirier-Beaudouin B, Durant J, Lebrun-Frenay C, Saïdi H, Seffer V, Ticchioni M, Chanalet S, Carsenti H, Harvey-Langton A, Laffon M, Cottalorda J, Pradier C, Dellamonica P, Vassallo M.

Heliyon. 2017 Feb 13;3(2):e00245. doi: 10.1016/j.heliyon.2017.e00245. eCollection 2017 Feb. Erratum in: Heliyon. 2017 Mar 16;3(3):e00259.

15.

Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case-referent surveillance.

Grimaldi-Bensouda L, Rossignol M, Koné-Paut I, Krivitzky A, Lebrun-Frenay C, Clet J, Brassat D, Papeix C, Nicolino M, Benhamou PY, Fain O, Costedoat-Chalumeau N, Courcoux MF, Viallard JF, Godeau B, Papo T, Vermersch P, Bourgault-Villada I, Breart G, Abenhaim L; PGRx-AD Study Group.

J Autoimmun. 2017 May;79:84-90. doi: 10.1016/j.jaut.2017.01.005. Epub 2017 Feb 9.

16.

Characteristics in limbic encephalitis with anti-adenylate kinase 5 autoantibodies.

Do LD, Chanson E, Desestret V, Joubert B, Ducray F, Brugière S, Couté Y, Formaglio M, Rogemond V, Thomas-Antérion C, Borrega L, Laurens B, Tison F, Curot J, De Brouker T, Lebrun-Frenay C, Delattre JY, Antoine JC, Honnorat J.

Neurology. 2017 Feb 7;88(6):514-524. doi: 10.1212/WNL.0000000000003586. Epub 2017 Jan 6.

PMID:
28062719
17.

A decreasing CD4/CD8 ratio over time and lower CSF-penetrating antiretroviral regimens are associated with a higher risk of neurocognitive deterioration, independently of viral replication.

Vassallo M, Fabre R, Durant J, Lebrun-Frenay C, Joly H, Ticchioni M, DeSalvador F, Harvey-Langton A, Dunais B, Laffon M, Cottalorda J, Dellamonica P, Pradier C.

J Neurovirol. 2017 Apr;23(2):216-225. doi: 10.1007/s13365-016-0490-z. Epub 2016 Nov 4.

PMID:
27815816
18.

CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy.

Pignolet B, Schwab N, Schneider-Hohendorf T, Bucciarelli F, Biotti D, Averseng-Peaureaux D, Outteryck O, Ongagna JC, de Sèze J, Brochet B, Ouallet JC, Debouverie M, Pittion S, Defer G, Derache N, Hautecoeur P, Tourbah A, Labauge P, Castelnovo G, Clavelou P, Berger E, Pelletier J, Rico A, Zéphir H, Laplaud D, Wiertlewski S, Camu W, Thouvenot E, Casez O, Moreau T, Fromont A, Vukusic S, Papeix C, Vermersch P, Comabella M, Lebrun-Frenay C, Wiendl H, Brassat D; BIONAT, SFSEP, and BEST-MS networks.

Neurology. 2016 Dec 6;87(23):2491-2494. Epub 2016 Nov 4. No abstract available.

PMID:
27815407
19.

MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study.

Tourbah A, Lebrun-Frenay C, Edan G, Clanet M, Papeix C, Vukusic S, De Sèze J, Debouverie M, Gout O, Clavelou P, Defer G, Laplaud DA, Moreau T, Labauge P, Brochet B, Sedel F, Pelletier J; MS-SPI study group.

Mult Scler. 2016 Nov;22(13):1719-1731. Epub 2016 Sep 1.

20.

Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study.

Peyro Saint Paul L, Creveuil C, Heinzlef O, De Seze J, Vermersch P, Castelnovo G, Cabre P, Debouverie M, Brochet B, Dupuy B, Lebiez P, Sartori É, Clavelou P, Brassat D, Lebrun-Frenay C, Daplaud D, Pelletier J, Coman I, Hautecoeur P, Tourbah A, Defer G.

J Neurol Sci. 2016 Apr 15;363:69-76. doi: 10.1016/j.jns.2016.02.012. Epub 2016 Feb 6.

PMID:
27000224
21.

Neuromyelitis optica: Contribution of therapeutic responses markers monitoring in patients given rituximab.

Romero G, Ticchioni M, Cohen M, Rosenthal-Allieri MA, Mondot L, Lebrun Frenay C.

Rev Neurol (Paris). 2016 Mar;172(3):220-4. doi: 10.1016/j.neurol.2015.12.004. Epub 2016 Feb 23. Review.

PMID:
26915311
22.

Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.

O'Connor P, Comi G, Freedman MS, Miller AE, Kappos L, Bouchard JP, Lebrun-Frenay C, Mares J, Benamor M, Thangavelu K, Liang J, Truffinet P, Lawson VJ, Wolinsky JS; Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group and the MRI-AC in Houston, Texas.

Neurology. 2016 Mar 8;86(10):920-30. doi: 10.1212/WNL.0000000000002441. Epub 2016 Feb 10. Erratum in: Neurology. 2016 Oct 4;87(14 ):1524.

23.

Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study.

Barbin L, Rousseau C, Jousset N, Casey R, Debouverie M, Vukusic S, De Sèze J, Brassat D, Wiertlewski S, Brochet B, Pelletier J, Vermersch P, Edan G, Lebrun-Frenay C, Clavelou P, Thouvenot E, Camdessanché JP, Tourbah A, Stankoff B, Al Khedr A, Cabre P, Papeix C, Berger E, Heinzlef O, Debroucker T, Moreau T, Gout O, Bourre B, Créange A, Labauge P, Magy L, Defer G, Foucher Y, Laplaud DA; CFSEP and OFSEP groups.

Neurology. 2016 Feb 23;86(8):771-8. doi: 10.1212/WNL.0000000000002395. Epub 2016 Jan 29.

24.

Country break-out session highlights.

Fazekas F, Gehring K, Gallo P, Lebrun-Frénay C, Moral E, Myhr KM.

Neurodegener Dis Manag. 2015;5(6 Suppl):31-7. doi: 10.2217/nmt.15.58. Review.

PMID:
26611270
25.

Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study.

Leray E, Vukusic S, Debouverie M, Clanet M, Brochet B, de Sèze J, Zéphir H, Defer G, Lebrun-Frenay C, Moreau T, Clavelou P, Pelletier J, Berger E, Cabre P, Camdessanché JP, Kalson-Ray S, Confavreux C, Edan G.

PLoS One. 2015 Jul 6;10(7):e0132033. doi: 10.1371/journal.pone.0132033. eCollection 2015.

26.

Virologically suppressed patients with asymptomatic and symptomatic HIV-associated neurocognitive disorders do not display the same pattern of immune activation.

Vassallo M, Durant J, Lebrun-Frenay C, Fabre R, Ticchioni M, Andersen S, DeSalvador F, Harvey-Langton A, Dunais B, Cohen-Codar I, Montagne N, Cua E, Fredouille-Heripret L, Laffon M, Cottalorda J, Dellamonica P, Pradier C.

HIV Med. 2015 Aug;16(7):431-40. doi: 10.1111/hiv.12246. Epub 2015 May 18.

27.

Isolated tumefactive demyelinating lesions: diagnosis and long-term evolution of 16 patients in a multicentric study.

Siri A, Carra-Dalliere C, Ayrignac X, Pelletier J, Audoin B, Pittion-Vouyovitch S, Debouverie M, Lionnet C, Viala F, Sablot D, Brassat D, Ouallet JC, Ruet A, Brochet B, Taillandier L, Bauchet L, Derache N, Defer G, Cabre P, de Seze J, Lebrun Frenay C, Cohen M, Labauge P.

J Neurol. 2015 Jul;262(7):1637-45. doi: 10.1007/s00415-015-7758-8. Epub 2015 May 1.

PMID:
25929666
28.

Early CNS neurodegeneration in radiologically isolated syndrome.

Azevedo CJ, Overton E, Khadka S, Buckley J, Liu S, Sampat M, Kantarci O, Lebrun Frenay C, Siva A, Okuda DT, Pelletier D.

Neurol Neuroimmunol Neuroinflamm. 2015 Apr 9;2(3):e102. doi: 10.1212/NXI.0000000000000102. eCollection 2015 Jun.

29.

High doses of biotin in chronic progressive multiple sclerosis: a pilot study.

Sedel F, Papeix C, Bellanger A, Touitou V, Lebrun-Frenay C, Galanaud D, Gout O, Lyon-Caen O, Tourbah A.

Mult Scler Relat Disord. 2015 Mar;4(2):159-69. doi: 10.1016/j.msard.2015.01.005. Epub 2015 Jan 24.

30.

Adult-onset genetic leukoencephalopathies: a MRI pattern-based approach in a comprehensive study of 154 patients.

Ayrignac X, Carra-Dalliere C, Menjot de Champfleur N, Denier C, Aubourg P, Bellesme C, Castelnovo G, Pelletier J, Audoin B, Kaphan E, de Seze J, Collongues N, Blanc F, Chanson JB, Magnin E, Berger E, Vukusic S, Durand-Dubief F, Camdessanche JP, Cohen M, Lebrun-Frenay C, Brassat D, Clanet M, Vermersch P, Zephir H, Outteryck O, Wiertlewski S, Laplaud DA, Ouallet JC, Brochet B, Goizet C, Debouverie M, Pittion S, Edan G, Deburghgraeve V, Le Page E, Verny C, Amati-Bonneau P, Bonneau D, Hannequin D, Guyant-Maréchal L, Derache N, Defer GL, Moreau T, Giroud M, Guennoc AM, Clavelou P, Taithe F, Mathis S, Neau JP, Magy L, Devoize JL, Bataillard M, Masliah-Planchon J, Dorboz I, Tournier-Lasserve E, Levade T, Boespflug Tanguy O, Labauge P.

Brain. 2015 Feb;138(Pt 2):284-92. doi: 10.1093/brain/awu353. Epub 2014 Dec 19.

PMID:
25527826
31.

[Gliomas and BRCA genes mutations: fortuitous association or imputability?].

Girardstein-Boccara L, Mari V, Met-Domestici M, Burel-Vandenbos F, Berthet P, Paquis P, Frenay MP, Lebrun-Frenay C.

Bull Cancer. 2014 Sep;101(9):795-802. doi: 10.1684/bdc.2014.1952. French.

PMID:
25295380
32.

[TNF inhibitors and myelitis: think about it, even lately].

Stève-Dumont M, Cohen M, Lebrun-Frenay C, Rocher F.

Therapie. 2014 Sep-Oct;69(5):473-7. doi: 10.2515/therapie/2014031. Epub 2014 Oct 1. French.

PMID:
25269140
33.

Risk for nevus transformation and melanoma proliferation and invasion during natalizumab treatment: four years of dermoscopic follow-up with immunohistological studies and proliferation and invasion assays.

Pharaon M, Tichet M, Lebrun-Frénay C, Tartare-Deckert S, Passeron T.

JAMA Dermatol. 2014 Aug;150(8):901-3. doi: 10.1001/jamadermatol.2013.9411. No abstract available.

PMID:
24919481
34.

[Bevacizumab associated with radiotherapy and temozolomide as a first line treatment for high-grade gliomas: one answer but too many questions].

Lebrun-Frenay C.

Rev Neurol (Paris). 2014 Apr;170(4):235-6. doi: 10.1016/j.neurol.2014.04.001. French. No abstract available.

PMID:
24776742
35.

Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders?

Vassallo M, Durant J, Biscay V, Lebrun-Frenay C, Dunais B, Laffon M, Harvey-Langton A, Cottalorda J, Ticchioni M, Carsenti H, Pradier C, Dellamonica P.

AIDS. 2014 Feb 20;28(4):493-501. doi: 10.1097/QAD.0000000000000096.

PMID:
24472743
36.

Milder multiple sclerosis course in patients with concomitant inflammatory bowel disease.

Zéphir H, Gower-Rousseau C, Salleron J, Simon O, Debouverie M, Le Page E, Bouhnik Y, Lebrun-Frenay C, Papeix C, Vigneron B, Allez M, Prin L, Cosnes J, Vermersch P, Colombel JF; CFSEP, GETAID and EPIMAD Groups.

Mult Scler. 2014 Jul;20(8):1135-9. doi: 10.1177/1352458513515081. Epub 2013 Dec 10.

PMID:
24326672
37.

Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects.

Grimaldi-Bensouda L, Guillemot D, Godeau B, Bénichou J, Lebrun-Frenay C, Papeix C, Labauge P, Berquin P, Penfornis A, Benhamou PY, Nicolino M, Simon A, Viallard JF, Costedoat-Chalumeau N, Courcoux MF, Pondarré C, Hilliquin P, Chatelus E, Foltz V, Guillaume S, Rossignol M, Abenhaim L; PGRx-AID Study Group.

J Intern Med. 2014 Apr;275(4):398-408. doi: 10.1111/joim.12155. Epub 2013 Nov 22.

38.

[Cavitary lesions in multiple sclerosis: multicenter study on twenty patients].

Corlobé A, Renard D, Goizet C, Berger E, Rumbach L, Robinson A, Dupuy D, Touzé E, Zéphir H, Vermersch P, Brochet B, Edan G, Deburghgraeve V, Créange A, Castelnovo G, Cohen M, Lebrun-Frenay C, Boespflug-Tanguy O, Labauge P.

Rev Neurol (Paris). 2013 Dec;169(12):965-9. doi: 10.1016/j.neurol.2013.02.010. Epub 2013 Oct 17. French.

PMID:
24139243
39.

[Symptomatic giant Virchow-Robin spaces].

Gronier S, Ayrignac X, Lamy C, Honnorat J, Thomas P, Lebrun-Frenay C, Labauge P.

Rev Neurol (Paris). 2013 Nov;169(11):898-902. doi: 10.1016/j.neurol.2013.05.003. Epub 2013 Oct 9. French.

PMID:
24119855
40.

[Is MRI monitoring useful in clinical practice in patients with multiple sclerosis? Comments].

Lebrun-Frenay C.

Rev Neurol (Paris). 2013 Nov;169(11):869-70. doi: 10.1016/j.neurol.2013.08.005. Epub 2013 Oct 4. French. No abstract available.

PMID:
24095287
41.

Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis.

International Multiple Sclerosis Genetics Consortium (IMSGC), Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kemppinen A, Cotsapas C, Shah TS, Spencer C, Booth D, Goris A, Oturai A, Saarela J, Fontaine B, Hemmer B, Martin C, Zipp F, D'Alfonso S, Martinelli-Boneschi F, Taylor B, Harbo HF, Kockum I, Hillert J, Olsson T, Ban M, Oksenberg JR, Hintzen R, Barcellos LF; Wellcome Trust Case Control Consortium 2 (WTCCC2); International IBD Genetics Consortium (IIBDGC), Agliardi C, Alfredsson L, Alizadeh M, Anderson C, Andrews R, Søndergaard HB, Baker A, Band G, Baranzini SE, Barizzone N, Barrett J, Bellenguez C, Bergamaschi L, Bernardinelli L, Berthele A, Biberacher V, Binder TM, Blackburn H, Bomfim IL, Brambilla P, Broadley S, Brochet B, Brundin L, Buck D, Butzkueven H, Caillier SJ, Camu W, Carpentier W, Cavalla P, Celius EG, Coman I, Comi G, Corrado L, Cosemans L, Cournu-Rebeix I, Cree BA, Cusi D, Damotte V, Defer G, Delgado SR, Deloukas P, di Sapio A, Dilthey AT, Donnelly P, Dubois B, Duddy M, Edkins S, Elovaara I, Esposito F, Evangelou N, Fiddes B, Field J, Franke A, Freeman C, Frohlich IY, Galimberti D, Gieger C, Gourraud PA, Graetz C, Graham A, Grummel V, Guaschino C, Hadjixenofontos A, Hakonarson H, Halfpenny C, Hall G, Hall P, Hamsten A, Harley J, Harrower T, Hawkins C, Hellenthal G, Hillier C, Hobart J, Hoshi M, Hunt SE, Jagodic M, Jelčić I, Jochim A, Kendall B, Kermode A, Kilpatrick T, Koivisto K, Konidari I, Korn T, Kronsbein H, Langford C, Larsson M, Lathrop M, Lebrun-Frenay C, Lechner-Scott J, Lee MH, Leone MA, Leppä V, Liberatore G, Lie BA, Lill CM, Lindén M, Link J, Luessi F, Lycke J, Macciardi F, Männistö S, Manrique CP, Martin R, Martinelli V, Mason D, Mazibrada G, McCabe C, Mero IL, Mescheriakova J, Moutsianas L, Myhr KM, Nagels G, Nicholas R, Nilsson P, Piehl F, Pirinen M, Price SE, Quach H, Reunanen M, Robberecht W, Robertson NP, Rodegher M, Rog D, Salvetti M, Schnetz-Boutaud NC, Sellebjerg F, Selter RC, Schaefer C, Shaunak S, Shen L, Shields S, Siffrin V, Slee M, Sorensen PS, Sorosina M, Sospedra M, Spurkland A, Strange A, Sundqvist E, Thijs V, Thorpe J, Ticca A, Tienari P, van Duijn C, Visser EM, Vucic S, Westerlind H, Wiley JS, Wilkins A, Wilson JF, Winkelmann J, Zajicek J, Zindler E, Haines JL, Pericak-Vance MA, Ivinson AJ, Stewart G, Hafler D, Hauser SL, Compston A, McVean G, De Jager P, Sawcer SJ, McCauley JL.

Nat Genet. 2013 Nov;45(11):1353-60. doi: 10.1038/ng.2770. Epub 2013 Sep 29.

42.

L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients.

Schwab N, Schneider-Hohendorf T, Posevitz V, Breuer J, Göbel K, Windhagen S, Brochet B, Vermersch P, Lebrun-Frenay C, Posevitz-Fejfár A, Capra R, Imberti L, Straeten V, Haas J, Wildemann B, Havla J, Kümpfel T, Meinl I, Niessen K, Goelz S, Kleinschnitz C, Warnke C, Buck D, Gold R, Kieseier BC, Meuth SG, Foley J, Chan A, Brassat D, Wiendl H.

Neurology. 2013 Sep 3;81(10):865-71. doi: 10.1212/WNL.0b013e3182a351fb. Epub 2013 Aug 7.

PMID:
23925765
43.

A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort.

Outteryck O, Ongagna JC, Brochet B, Rumbach L, Lebrun-Frenay C, Debouverie M, Zéphir H, Ouallet JC, Berger E, Cohen M, Pittion S, Laplaud D, Wiertlewski S, Cabre P, Pelletier J, Rico A, Defer G, Derache N, Camu W, Thouvenot E, Moreau T, Fromont A, Tourbah A, Labauge P, Castelnovo G, Clavelou P, Casez O, Hautecoeur P, Papeix C, Lubetzki C, Fontaine B, Couturier N, Bohossian N, Clanet M, Vermersch P, de Sèze J, Brassat D; BIONAT Network,; CFSEP.

Eur J Neurol. 2014;21(1):40-8. doi: 10.1111/ene.12204. Epub 2013 Jun 12.

PMID:
23895407
44.

Relevance of lipopolysaccharide levels in HIV-associated neurocognitive impairment: the Neuradapt study.

Vassallo M, Dunais B, Durant J, Carsenti-Dellamonica H, Harvey-Langton A, Cottalorda J, Ticchioni M, Laffon M, Lebrun-Frenay C, Dellamonica P, Pradier C.

J Neurovirol. 2013 Aug;19(4):376-82. doi: 10.1007/s13365-013-0181-y. Epub 2013 Jul 12.

PMID:
23846287
45.

Treat patients with radiologically isolated syndrome when the MRI brain scan shows dissemination in time: yes.

Brassat D, Lebrun-Frenay C; Club Francophone de la SEP.

Mult Scler. 2012 Nov;18(11):1531-2. doi: 10.1177/1352458512462268. No abstract available.

PMID:
23100524
46.

A benign form of neuromyelitis optica: does it exist?

Collongues N, Cabre P, Marignier R, Zéphir H, Papeix C, Audoin B, Lebrun-Frenay C, Pelletier J, Fontaine B, Vermersch P, Confavreux C, de Seze J; Group Members for NOMADMUS and CF-SEP.

Arch Neurol. 2011 Jul;68(7):918-24. doi: 10.1001/archneurol.2011.127.

PMID:
21747032
47.

Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility.

Couturier N, Bucciarelli F, Nurtdinov RN, Debouverie M, Lebrun-Frenay C, Defer G, Moreau T, Confavreux C, Vukusic S, Cournu-Rebeix I, Goertsches RH, Zettl UK, Comabella M, Montalban X, Rieckmann P, Weber F, Müller-Myhsok B, Edan G, Fontaine B, Mars LT, Saoudi A, Oksenberg JR, Clanet M, Liblau RS, Brassat D.

Brain. 2011 Mar;134(Pt 3):693-703. doi: 10.1093/brain/awr010.

PMID:
21354972
48.

Prior suggestive symptoms in one-third of patients consulting for a "first" demyelinating event.

Gout O, Lebrun-Frenay C, Labauge P, Le Page GE, Clavelou P, Allouche S; PEDIAS Group.

J Neurol Neurosurg Psychiatry. 2011 Mar;82(3):323-5. doi: 10.1136/jnnp.2008.166421. Epub 2010 Nov 19.

PMID:
21097550
49.

Evolution of nevi during treatment with natalizumab: A prospective follow-up of patients treated with natalizumab for multiple sclerosis.

Castela E, Lebrun-Frenay C, Laffon M, Rocher F, Cohen M, Leccia NC, Bahadoran P, Lacour JP, Ortonne JP, Passeron T.

Arch Dermatol. 2011 Jan;147(1):72-6. doi: 10.1001/archdermatol.2010.243. Epub 2010 Sep 20.

PMID:
20855675
50.

EGFR immunolabeling pattern may discriminate low-grade gliomas from gliosis.

Burel-Vandenbos F, Benchetrit M, Miquel C, Fontaine D, Auvergne R, Lebrun-Frenay C, Cardot-Leccia N, Michiels JF, Paquis-Flucklinger V, Virolle T.

J Neurooncol. 2011 Apr;102(2):171-8. doi: 10.1007/s11060-010-0308-4. Epub 2010 Jul 24.

PMID:
20652725

Supplemental Content

Loading ...
Support Center